Search results for "Acute generalized exanthematous pustulosis"

showing 3 items of 3 documents

A case of cefditoren‐induced Acute Generalized Exanthematous Pustulosis during COVID‐19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an …

2020

Abstract We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID‐19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.

0301 basic medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyDermatologymedicine.disease_causeLetter to EditorSARS‐CoV‐2030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCOVID‐19PandemicSeverity of illnessmedicineSevere Cutaneous Adverse Reactions (SCARs)Coronavirusbusiness.industryFollow up studiesAcute Generalized Exanthematous Pustulosis (AGEP)Acute generalized exanthematous pustulosismedicine.diseaseDermatologyInfectious DiseasesbusinessCefditorenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Systematic review of BRAF/MEK inhibitors‐induced Severe Cutaneous Adverse Reactions (SCARs)

2020

Severe cutaneous adverse reactions (SCARs) [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic syndrome (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed eruption (GBFE)] are severe drug reactions that often require hospitalization and could be fatal. BRAF and MEK inhibitors (BRAF/MEKi) are a standard of care in patients with BRAF-mutated metastatic melanomas. These agents are administered until disease progression or unacceptable toxicity occurs. This review has focus on BRAF/MEKi-induced SCARs. A systematic search of the following terms: 'vemurafenib', 'cobimetinib', 'dabrafenib', 'trametinib',…

Proto-Oncogene Proteins B-rafmedicine.medical_specialtyDermatologyCicatrix030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansVemurafenibRetrospective StudiesMitogen-Activated Protein Kinase KinasesTrametinibCobimetinibbusiness.industryBinimetinibDabrafenibAcute generalized exanthematous pustulosismedicine.diseaseDermatologyToxic epidermal necrolysisInfectious DiseasesAcute Generalized Exanthematous PustulosischemistryDrug Hypersensitivity SyndromeStevens-Johnson Syndrome030220 oncology & carcinogenesisbusinessmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Synthesis of the Data on COVID-19 Skin Manifestations: Underlying Mechanisms and Potential Outcomes

2021

Abstract The incidence of coronavirus disease 2019 (COVID-19)-related skin manifestations has progressively grown, in parallel with the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. The available evidence indicates that cutaneous signs are heterogeneous and can be divided as follows: a) erythematous rashes, b) lesions of vascular origin, c) vesicular rashes, d) urticarial rashes, and e) acute generalized exanthematous pustulosis (AGEP), erythema multiforme (EM) and other polymorphic/atypical reactions. Most cutaneous manifestations appear simultaneously or after respiratory and/or systemic symptoms such as fever, even if rarely urticaria has been reported as…

medicine.medical_specialtycutaneous manifestationscutaneous manifestationbusiness.industrySARS-CoV-2COVID-19DermatologyDiseaseReviewmedicine.diseaseAcute generalized exanthematous pustulosisDermatologyVirusHypersensitivity reactionImmune systemmedicineskin rashesErythema multiformeRespiratory systemChilblainsbusiness
researchProduct